In conclusion, the promising results obtained with mouse models of DS and more recently in human DS-iPSCs, provides good reason for optimism that DYRK1A inhibition may well be a relevant target to improve cognition of patients with DS. This evidence concerns the gene DYRK1A and Dravet syndrome.